SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:prod.swepub.kib.ki.se:147786460"
 

Search: onr:"swepub:oai:prod.swepub.kib.ki.se:147786460" > Inhibition of the u...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound

Giovannucci, TA (author)
Karolinska Institutet
Salomons, FA (author)
Karolinska Institutet
Haraldsson, M (author)
Karolinska Institutet
show more...
Elfman, LHM (author)
Wickstrom, M (author)
Karolinska Institutet
Young, P (author)
Lundback, T (author)
Eirich, J (author)
Altun, M (author)
Karolinska Institutet
Jafari, R (author)
Karolinska Institutet
Gustavsson, AL (author)
Karolinska Institutet
Johnsen, JI (author)
Karolinska Institutet
Dantuma, NP (author)
Karolinska Institutet
show less...
 (creator_code:org_t)
2021-10-06
2021
English.
In: Cell death & disease. - : Springer Science and Business Media LLC. - 2041-4889. ; 12:10, s. 914-
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Malignant cells display an increased sensitivity towards drugs that reduce the function of the ubiquitin-proteasome system (UPS), which is the primary proteolytic system for destruction of aberrant proteins. Here, we report on the discovery of the bioactivatable compound CBK77, which causes an irreversible collapse of the UPS, accompanied by a general accumulation of ubiquitylated proteins and caspase-dependent cell death. CBK77 caused accumulation of ubiquitin-dependent, but not ubiquitin-independent, reporter substrates of the UPS, suggesting a selective effect on ubiquitin-dependent proteolysis. In a genome-wide CRISPR interference screen, we identified the redox enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1) as a critical mediator of CBK77 activity, and further demonstrated its role as the compound bioactivator. Through affinity-based proteomics, we found that CBK77 covalently interacts with ubiquitin. In vitro experiments showed that CBK77-treated ubiquitin conjugates were less susceptible to disassembly by deubiquitylating enzymes. In vivo efficacy of CBK77 was validated by reduced growth of NQO1-proficient human adenocarcinoma cells in nude mice treated with CBK77. This first-in-class NQO1-activatable UPS inhibitor suggests that it may be possible to exploit the intracellular environment in malignant cells for leveraging the impact of compounds that impair the UPS.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view